Supriya Lifescience Gets Brazil's Nod For Mental Illness Drug
Supriya Lifescience Ltd. received approval for its mental illness drug Esketamine Hydrochloride from Brazil's health authority, 'Agência Nacional de Vigilância Sanitária', according to an exchange filing on Monday.
Esketamine Hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the Latin America market, the filing stated.
This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing, it added.
Supriya Lifescience added that it was the first company to receive approval from Brazil for Esketamine Hydrochloride.
"Our global presence is strengthened by the CADIFA (Brazil's letter of suitability for pharmaceutical products) approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil," said Satish Wagh, the executive chairman and director of Supriya Lifescience.
Atorvastatin Patent Filing
Supriya Lifescience also informed the exchanges that it has submitted "ground-breaking patent application" for an enhanced, and low-cost method of atorvastatin synthesis. Atorvastatin is a key treatment for controlling cholesterol and preventing cardiovascular disease, the company pointed out.
The drugmaker added that its ground-breaking technique makes medicines more affordable for patients by increasing their efficacy while reducing production costs.
"Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin," Wagh said.
Shares of Supriya Lifescience closed 1.28% higher at Rs 783.8 apiece on the NSE, compared to a 0.24% increase in the benchmark Nifty 50. The stock has risen by 149% on a year-to-date basis and by 190% over the past 12 months.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.